Jubilant Life Sciences Ltd. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

Jubilant Life Sciences Ltd. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Jubilant Life Sciences Ltd. and its competitors. This provides our Clients with a clear understanding of Jubilant Life Sciences Ltd. position in the Pharmaceuticals and Biotechnology Industry.

Scope

• The report contains the company’s profile and data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
• The SWOT-analysis provides information about the company’s strengths, weaknesses, opportunities, and possible threats against it.
• The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency.
• It also shows the company’s income statement and ratio trend-charts, with balance sheets and cash flows presented on an annual and quarterly basis.
• Company’s financial ratios are directly compared with those of its competitors through industry averages.
• The report provides relevant news, an analysis of PR-activity, and stock price movements.
• The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms.

The benefits of buying the Report are as follows:

• Readers will gain an unrivalled in-depth knowledge about the company.
• The report will help the management of your business environment. This will be achieved through the report’s unique analysis of both the market and company’s competitors, and by providing detailed information about the internal and external factors that affect the relevant industry.
• Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
• The report will help you to find prospective partners and suppliers.
• The annual profitability data provided in the report will assist and strengthen your company’s decision-making processes.

About Jubilant Life Sciences Ltd.

Jubilant Organosys Limited, an integrated pharmaceutical company, provides custom research and manufacturing services (CRAMS), and drug discovery and development services (DDDS) in India.

The company has operations across the pharmaceuticals value chain ranging from drug discovery services, custom research and manufacturing services, advance intermediates and fine chemicals to active pharmaceutical ingredients, dosage forms, and regulatory affairs services.

Segments

The company’s primary business segments are organized around customers, on industry and product lines as under:

Pharmaceuticals and Life Sciences Products & Services: This segment includes Active Pharmaceuticals Ingredients (APIs) and Custom Research & Manufacturing Services.

Industrial & Performance Products: This segment includes Organic Intermediates, Agri and Animal Nutrition Products, Industrial products for tyres, textiles and coatings; Consumer Products for woodworking solutions; and Food Polymers and Specialty Gases.

PHARMACEUTICALS AND LIFE SCIENCES PRODUCTS & SERVICES (PLSPS)

The company’s PLSPS business is divided into the following sub-segments: CRAMS - Custom Research & Manufacturing Services, Drug Discovery and Development Services, Generic Dosage Forms, and Healthcare.

CRAMS

The company is a manufacturer of Pyridine and its derivatives worldwide. It provides a range of fine chemicals and advanced intermediates to the global pharmaceuticals, agrochemicals, and life sciences industry. These comprise pyridine and its derivatives - which are used as solvents, basic building blocks, and advanced intermediates with application in the pharmaceuticals and agrochemicals industry. Within Proprietary Products, the company has a library of approximately 150 products which are developed in house.

The company, under its nutritional products business, makes Niacin and Niacinamide. It is integrated into manufacturing of Beta Picoline, which is the basic raw material used in the making of nutritional products.

The company, under Exclusive Synthesis, offers research, development, and manufacturing services for intermediates and APIs for New Chemical Entities (NCEs) and in market products from development to commercialization stage.

Active Pharmaceutical Ingredients (APIs): The company, under APIs, focuses on therapeutic segments, such as Central Nervous System (CNS), Cardiovascular System (CVS), Gastro Intestinal (GI), and Anti-Infectives. It has 19 products under active development. Its APIs are exported worldwide, into emerging as well as developed markets. The main markets are North America, South America, Europe, Japan, Korea, CIS Countries, and Australia.

CMO of Sterile Injectables and Non-Sterile Products: The CMO business services the range of life sciences industry requirements - from large scale pharmaceutical companies to virtual biotechnology organizations, with two independently branded CMO organizations in North America: Hollister-Stier contract manufacturing located in Spokane, Washington, USA and Draxis Pharma located in Montreal, Canada, and its own in-house solid dosage form capabilities.

The Hollister-Stier facility is focused on the delivery of clinical and commercial fill and finish services for sterile parenteral pharmaceuticals, utilizing both liquid and lyophilisation capabilities.

Speciality Pharmaceuticals: Speciality Pharmaceuticals business comprises Radiopharmaceuticals and Allergenic Extracts. Nuclear medicine imaging and therapeutic agents are the focus of the Radiopharmaceuticals Division ‘DRAXIMAGE’ which develops, manufactures, and markets diagnostic imaging and therapeutic radiopharmaceutical products for the global marketplace. Products marketed by the radiopharmaceutical division include a line of lyophilized Technetium-99m kits used in nuclear medicine imaging procedures and a line of imaging and therapeutic products labeled with a variety of isotopes including Sodium Iodide I-131.

Drug Discovery and Development Services (DDDS)

The Drug Discovery and Development Services business is integrated across three subsidiaries, Jubilant Biosys, Jubilant Chemsys and Clinsys Clinical Re

Contents

RESEARCH METHODOLOGY

DISCLAIMER

1. JUBILANT LIFE SCIENCES LTD. COMPANY PROFILE

1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History

2. JUBILANT LIFE SCIENCES LTD. BUSINESS OVERVIEW

2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units

3. JUBILANT LIFE SCIENCES LTD. SWOT ANALYSIS

3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats

4. JUBILANT LIFE SCIENCES LTD. FINANCIAL ANALYSIS

4.1. Financial Statements
  4.1.1. Income Statement
  4.1.2. Balance Sheet
  4.1.3. Cash Flow
4.2. Financial Ratios
  4.2.1. Profitability
  4.2.2. Margin Analysis
  4.2.3. Asset Turnover
  4.2.4. Credit Ratios
  4.2.5. Long-Term Solvency
  4.2.6. Growth Over Prior Year
  4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot

5. JUBILANT LIFE SCIENCES LTD. COMPETITORS AND INDUSTRY ANALYSIS

5.1. Jubilant Life Sciences Ltd. Direct Competitors
5.2. Comparison of Jubilant Life Sciences Ltd. and Direct Competitors Financial Ratios
5.3. Comparison of Jubilant Life Sciences Ltd. and Direct Competitors Stock Charts
5.4. Jubilant Life Sciences Ltd. Industry Analysis
  5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. Jubilant Life Sciences Ltd. Industry Position Analysis

6. JUBILANT LIFE SCIENCES LTD. NEWS & EVENTS

6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events

7. JUBILANT LIFE SCIENCES LTD. EXPERTS REVIEW

7.1. Experts Opinion
7.2. Experts Estimates

APPENDIX 1: RATIO DEFINITIONS

LIST OF TABLES

Table 1. Jubilant Life Sciences Ltd. Key Facts
Table 2. Jubilant Life Sciences Ltd. Profitability
Table 3. Jubilant Life Sciences Ltd. Management Effectiveness
Table 4. Jubilant Life Sciences Ltd. Income Statement Key Figures
Table 5. Jubilant Life Sciences Ltd. Balance Sheet Key Figures
Table 6. Jubilant Life Sciences Ltd. Cash Flow Statement Key Figures
Table 7. Financial Performance Abbreviation Guide
Table 8. Jubilant Life Sciences Ltd. Key Executives
Table 9. Jubilant Life Sciences Ltd. Key Executives Biographies *
Table 10. Jubilant Life Sciences Ltd. Key Executives Compensations *
Table 11. Jubilant Life Sciences Ltd. Key Executives Stock Options *
Table 12. Jubilant Life Sciences Ltd. Major Shareholders
Table 13. Jubilant Life Sciences Ltd. History
Table 14. Jubilant Life Sciences Ltd. Products
Table 15. Jubilant Life Sciences Ltd. Revenues by Product
Table 16. Jubilant Life Sciences Ltd. Revenues by Region
Table 17. Jubilant Life Sciences Ltd. Offices and Representations
Table 18. Jubilant Life Sciences Ltd. SWOT Analysis
Table 19. Jubilant Life Sciences Ltd. Income Statement 2008-2011 Including 4-years Trends
Table 20. Jubilant Life Sciences Ltd. Income Statement Latest 4 Quarters Including Trends
Table 21. Jubilant Life Sciences Ltd. Balance Sheet 2008-2011 Including Trends
Table 22. Jubilant Life Sciences Ltd. Balance Sheet Latest 4 Quarters Including Trends
Table 23. Jubilant Life Sciences Ltd. Cash Flow 2008-2011 Including Trends
Table 24. Jubilant Life Sciences Ltd. Cash Flow Latest 4 Quarters Including Trends
Table 25. Jubilant Life Sciences Ltd. Profitability Ratios
Table 26. Jubilant Life Sciences Ltd. Margin Analysis Ratios
Table 27. Jubilant Life Sciences Ltd. Asset Turnover Ratios
Table 28. Jubilant Life Sciences Ltd. Credit Ratios
Table 29. Jubilant Life Sciences Ltd. Long-Term Solvency Ratios
Table 30. Jubilant Life Sciences Ltd. Financial Ratios Growth Over Prior Year
Table 31. Jubilant Life Sciences Ltd. Capital Market Snapshot
Table 32. Jubilant Life Sciences Ltd. Direct Competitors Key Facts
Table 33. Jubilant Life Sciences Ltd. Direct Competitors Profitability Ratios
Table 34. Jubilant Life Sciences Ltd. Direct Competitors Margin Analysis Ratios
Table 35. Jubilant Life Sciences Ltd. Direct Competitors Asset Turnover Ratios
Table 36. Jubilant Life Sciences Ltd. Direct Competitors Credit Ratios
Table 37. Jubilant Life Sciences Ltd. Direct Competitors Long-Term Solvency Ratios
Table 38. Pharmaceuticals and Biotechnology Industry Statistics
Table 39. Jubilant Life Sciences Ltd. Industry Position
Table 40. Jubilant Life Sciences Ltd. vs. Industry Income Statement Analysis
Table 41. Jubilant Life Sciences Ltd. vs. Industry Balance Sheet Analysis
Table 42. Jubilant Life Sciences Ltd. vs. Industry Cash Flow Analysis
Table 43. Jubilant Life Sciences Ltd. vs. Industry Ratios Comparison
Table 44. Jubilant Life Sciences Ltd. Consensus Recommendations*
Table 45. Jubilant Life Sciences Ltd. Analyst Recommendation Summary*
Table 46. Jubilant Life Sciences Ltd. Price Target Summary*
Table 47. Jubilant Life Sciences Ltd. Experts Recommendation Trends*
Table 48. Jubilant Life Sciences Ltd. Revenue Estimates Analysis*
Table 49. Jubilant Life Sciences Ltd. Earnings Estimates Analysis*
Table 50. Jubilant Life Sciences Ltd. Historical Surprises*
Table 51. Jubilant Life Sciences Ltd. Revenue Estimates Trend*
Table 52. Jubilant Life Sciences Ltd. Earnings Estimates Trend*
Table 53. Jubilant Life Sciences Ltd. Revenue Revisions*
Table 54. Jubilant Life Sciences Ltd. Earnings Revisions*

LIST OF FIGURES

Figure 1. Jubilant Life Sciences Ltd. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Figure 2. Jubilant Life Sciences Ltd. Profit Margin Chart
Figure 3. Jubilant Life Sciences Ltd. Operating Margin Chart
Figure 4. Jubilant Life Sciences Ltd. Return on Equity (ROE) Chart
Figure 5. Jubilant Life Sciences Ltd. Return on Assets (ROA) Chart
Figure 6. Jubilant Life Sciences Ltd. Debt to Equity Chart
Figure 7. Jubilant Life Sciences Ltd. Current Ratio Chart
Figure 8. Jubilant Life Sciences Ltd. 1-year Stock Charts
Figure 9. Jubilant Life Sciences Ltd. 5-year Stock Charts
Figure 10. Jubilant Life Sciences Ltd. vs. Main Indexes 1-year Stock Chart
Figure 11. Jubilant Life Sciences Ltd. vs. Direct Competitors 1-year Stock Charts
Figure 12. Jubilant Life Sciences Ltd. Article Density Chart

* – Data availability depends on company’s security policy.
The complete financial data is available for public traded companies.

The above Company Fundamental Report is a half-ready report.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get up-to-date version for the same price.